Drug Trial Radar · NCT06526182
A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
520
Planned (sponsor's estimate)
Start
Jul 3, 2024
Primary completion
Apr 25, 2027
Study completion Apr 25, 2027
Sponsor
- Lead sponsor
- Almirall, S.A.Industry
- Sponsor type
- Industry
- First posted
- Jul 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe AD in Part 1 and to describe how similar is the current maintenance dosing regimen of lebrikizumab 250 mg every 4 weeks (Q4W) to the new proposed; lebrikizumab 500 mg every 12 weeks (Q12W), in terms of efficacy, safety, PK, ADA and blood biomarkers.
Conditions
- Dermatitis, Atopic
- Eczema
Interventions
LebrikizumabBiological
Lebrikizumab solution for injection administered subcutaneously.
PlaceboOther
Lebrikizumab Matching placebo solution for injection administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Score Less than or Equal to (<=) 7 at Week 24Time frame: At Week 24
- Part 2: Percentage of Participants Achieving EASI 75 at Week 36Time frame: At Week 36
- Part 2: Percentage of Participants with an IGA Score of 0 or 1 and a Reduction >=2 PointsTime frame: From Baseline (Part 1) up to Week 36
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Hospital General Universitario Dr. Balmis
Alicante, Spain
Hospital del Mar - Parc de Salut Mar
Barcelona, Spain
Hospital Universitario Clínico San Cecilio
Granada, Spain
Consorci Hospital General Universitari de València
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.